Ischemic brain injury triggers neuronal cell death by apoptosis via caspase activation and by
necroptosis through activation of the receptor-interacting protein kinases (RIPK) associated
with the tumor necrosis factor-alpha (TNF-α)/death receptor. Recent evidence shows RIPK
inhibitors are neuroprotective and alleviate ischemic brain injury in a number of animal
models, however, most have not yet undergone clinical trials and safety in humans remains
in question. Dabrafenib, originally identified as a B-raf inhibitor that is currently used to treat …